Results 261 to 270 of about 209,258 (305)

Research progress of mTOR inhibitors

European Journal of Medicinal Chemistry, 2020
Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr) protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein family. mTOR exists as two types of protein complex: mTORC1 and mTORC2, which act as central controller regulating processes of cell metabolism, growth, proliferation ...
Yifan Chen, Xiaoping Zhou
openaire   +2 more sources

mTOR inhibitors in cancer therapy

Cancer Letters, 2012
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors.
Yekaterina Y, Zaytseva, Joseph D, Valentino, Pat, Gulhati, B Mark, Evers   +3 more
openaire   +2 more sources

Pharmacodynamic Monitoring of mTOR Inhibitors

Therapeutic Drug Monitoring, 2019
Abstract: Pharmacodynamic (PD) monitoring may complement routine pharmacokinetic monitoring of mTOR inhibitors (mTORis) in an attempt to better guide individualized sirolimus (SRL) or everolimus (EVR) treatment after organ transplantation. This review focuses on current knowledge about PD biomarkers for personalized mTORi therapies. Different
Olga, Millán, Eberhard, Wieland, Pierre, Marquet, Mercè, Brunet   +3 more
openaire   +2 more sources

mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy

Hematology/Oncology Clinics of North America, 2012
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great responses obtained in tumors addicted to specific mutations or overactivation of key members of the mTOR pathway (HiF1α in RCC, cyclin D1 in MCL, or TSC in SEGA),
Alejandro, Gomez-Pinillos, Anna C, Ferrari   +1 more
openaire   +2 more sources

Replacing calcineurin inhibitors with mTOR inhibitors in children

Pediatric Transplantation, 2005
Abstract:  A highly selected subject group comprising pediatric recipients of liver (n = 36) and small intestine alone (n = 1) or multivisceral graft (n = 2) were converted to sirolimus maintenance therapy for tacrolimus‐related side effects (n = 32) or by primary intent (n = 7).
Rakesh, Sindhi, Joseph, Seward, George, Mazariegos, Kyle, Soltys, Lynn, Seward, Amy, Smith, Beverly, Kosmach, Raman, Venkataramanan   +7 more
openaire   +2 more sources

Adverse events associated with mTOR inhibitors

Expert Opinion on Drug Safety, 2012
The mTOR (mechanistic target of rapamycin, formerly known as mammalian target of rapamycin) kinase is centrally involved in the regulation of cell growth and metabolism in response to intra- and extracellular energetic stimuli and growth factors. The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR ...
Nicolas, Pallet, Christophe, Legendre
openaire   +2 more sources

[mTOR inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 2010
Mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving proliferation, cell survival, and angiogenesis. These pathways are frequently abnormally regulated in cancer.
openaire   +1 more source

mTOR Inhibitors: Facing New Challenges Ahead

Current Medicinal Chemistry, 2011
The enzyme mammalian target of rapamycin (mTOR) is a master kinase that regulates several critical intracellular processes. It is now well established that this enzyme has a key role in cancer and its inhibition as therapeutic anti-cancer strategy is well recognised.
I, Mavrommati, T, Maffucci
openaire   +2 more sources

mTOR Inhibitors in Polycystic Kidney Disease

New England Journal of Medicine, 2010
Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of inherited renal failure1 that is characterized by the progressive formation of renal cysts, which leads to end-stage renal disease in mid-adulthood. Furthermore, massive renal enlargement has a number of untoward consequences, including chronic pain, hypertension, and cyst ...
Terry, Watnick, Gregory G, Germino
openaire   +2 more sources

[mTOR inhibitor].

Gan to kagaku ryoho. Cancer & chemotherapy, 2011
Mammalian target of rapamycin(mTOR)exists downstream in the PI3K/AKT signal transmission pathway that is constantly activated in many cancers. It regulates translation of mRNA that codes for proteins involved in survival signals, such as for the cell cycle and apoptosis, by phosphorylation of p70S6K and 4E-BP1 that are further downstream.
openaire   +1 more source